Key Developments: BioProspect Ltd (BPO.AX)

BPO.AX on Australia Stock Exchange

28 Aug 2014
Price Change (% chg)

$0.00 (+33.33%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

BioProspect Ltd announces issue of shares
Friday, 16 May 2014 03:55am EDT 

BioProspect Ltd:Issues 275,000,000 shares at an issue price of A$0.002 per share.Purpose of issue is part consideration for licence and option deed with Heartlink.  Full Article

BioProspect Ltd announces appointment of Non Executive Chairman
Monday, 28 Apr 2014 06:00pm EDT 

BioProspect Limited:Says Vince Fayad has been appointed as the Non Executive Chairman.  Full Article

BioProspect Ltd acquires Invatec/Heartlink's diagnostic heart rate variability (HRV) technology
Sunday, 13 Apr 2014 07:50pm EDT 

BioProspect Ltd:Says that it will proceed with acquisition of Invatec/Heartlink’s Heart Rate Variability (HRV) technology following completion of favourable due diligence exercise.HRV technology, which analyses the heart rate variability of patient, is a truly objective quantitative test for mental health, including depression.Board of BioProspect has exercised both options to acquire initial interest in Invatec and to licence Heartlink technology, which together comprise the ground-breaking HRV technology.BPO will initially acquire 35 pct. of Invatec and worldwide license to HRV technology by funding future development of technology.Once this is complete, BPO may exercise a further option to fully acquire entire patent portfolio of Heartlink and to increase its stake in Invatec to 80 pct.  Full Article

BioProspect Ltd not to pay H1 2014 dividend
Friday, 28 Feb 2014 03:33am EST 

BioProspect Ltd:Says no dividend has been declares for six months ended Dec. 31, 2013.  Full Article

BioProspect Ltd raises $1,000,000 via an issue of convertible notes
Sunday, 26 Jan 2014 06:00pm EST 

BioProspect Ltd:Says it has raised A$1,000,000 via an issue of Convertible Notes (Note) to a consortium of existing shareholders.Says the facility is to be drawn down in three tranches.Says $400,000 is available immediately upon completion of Due Diligence and the decision to proceed with Stage 1 of the Invatec transaction.Says tranche two $300,000 is available upon commencement of an Independent Validation study of the Invatec Technology.Says Tranche three $300,000 is available as needed following the second draw down but must be drawn by June. 30, 2015.Says each Convertible Note issued would have a face value of $25,000 conversion price of the lesser of 0.3 cents per ordinary share.Says the capital raised under the Convertible Notes Issue will be used to fund the evaluation of the Invatec Transaction and provide for the current working capital requirements of the company.  Full Article

BioProspect Ltd announces option to acquire 80% of Invatec Health Pty Ltd
Wednesday, 4 Dec 2013 05:55pm EST 

BioProspect Ltd:Says that it has entered into agreements which have allowed it to bring together a project for the quantitative diagnosis of depression and other mental health disorders.Says BPO has the option to acquire 80% of Invatec Health Pty Ltd (Invatec) by a 2 stage transaction.Says Invatec has developed a method for diagnosing Mental Health disorders including Depression, Generalised Anxiety Disorder, Acute Psychosis and Panic Disorder by monitoring a subject’s heart rate data.Says in a separate agreement with Heartlink Limited (Heartlink), BPO has an option to acquire an exclusive licence to use and exploit patents covering the project technology (stage 1 option) with a further option to acquire the entire patent suite and all associated IP (stage 2 option).  Full Article

BioProspect Ltd Announces Management Changes
Tuesday, 29 Oct 2013 04:22am EDT 

BioProspect Ltd announced that Mr Willesee the Chairman of the Company is retiring. The appointment of a new Director and Chairman will be announced at the Annual General Meeting to be held on November 15, 2013.  Full Article

BioProspect Ltd Does Not Declare Final Dividend
Sunday, 1 Sep 2013 07:55pm EDT 

BioProspect Ltd announced that no final dividend was declared for fiscal 2013.  Full Article

BioProspect Ltd Not To Pay H1 2013 Dividend
Wednesday, 27 Feb 2013 11:02pm EST 

BioProspect Ltd announced that no interim dividend has been declared for the first half of fiscal 2013.  Full Article

BioProspect Ltd Announces Change Of Chief Executive Officer
Sunday, 18 Nov 2012 06:50pm EST 

BioProspect Ltd announced that Mr. Peter May will contemporaneously cease as Chief Executive Officer, but will continue to provide executive services associated with the Company's biotech assets and projects. He was appointed as a non-executive director, effective November 19, 2012.  Full Article

No consensus analysis data available.
Search Stocks